Provided is a radioactive labeled compound that can detect a secondary mutation of an epidermal growth factor receptor and which is a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof. In Formula (1), R1 is a group represented by Formula (a), (b) or (c), R2 is a group represented by Formula (d) or (e), and Y is -NH- or -O-.